RESUMEN
The use of invertebrate hemolymph chemistry analysis has the potential to become a major diagnostic tool. The goal of this study was to generate statistically sound hemolymph reference ranges from healthy tarantulas. Hemolymph was drawn from wild caught, acclimatized, and apparently healthy female Chilean rose tarantulas Grammostola rosea (Walkenaer, 1837) ( n = 43) using a modified technique. Hemolymph samples were separately analyzed using the Avian-Reptilian Profile Plus reagent rotor for VetScan® for the following chemistries: aspartate aminotransferase, bile acids, creatine kinase, uric acid, glucose, total calcium, phosphorus, total protein, albumin, potassium, and sodium. With this method the authors were able to establish statistically sound reference ranges for aspartate aminotransferase, creatine kinase, glucose, phosphorus, and total protein. Further in situ studies will determine the practical usability of these values in the evaluation of tarantula health.
Asunto(s)
Hemolinfa/química , Arañas/fisiología , Albúminas/química , Animales , Aspartato Aminotransferasas/química , Aspartato Aminotransferasas/metabolismo , Calcio/química , Creatina Quinasa , Femenino , Ácido Glucárico/química , Fósforo , Potasio/química , Proteínas/química , Valores de Referencia , Sodio/química , Ácido Úrico/químicaRESUMEN
BACKGROUND: Anaemia and iron deficiency are common after post-bariatric abdominoplasty, which can involve removal of large areas of skin with associated blood loss. Because the oral absorbability of iron is reduced after bariatric surgery (through reduced intake, reduction of gastric acid secretion for conjugation of iron, and separation of the iron-absorptive areas of the duodenum and jejunum), it has been hypothesised that postoperative intravenous iron supplementation might be used to treat anaemia and iron deficiency in patients submitted to post-bariatric plastic surgeries. We aimed to assess whether intravenous iron administered postoperatively in post-bariatric abdominoplasty could result in increased blood haemoglobin concentrations compared with oral iron supplementation. METHODS: In this open-label, randomised, superiority trial, we recruited women aged 18-55 years undergoing post-bariatric abdominoplasty at two public tertiary referral hospitals in São Paulo, Brazil. Eligible women had been treated for previous obesity with bariatric surgery using the vertical banded gastroplasty technique with Roux-en-Y gastric bypass by laparotomy; had grade III contour deformity via the Pittsburgh rating scale; and had a post-bariatric body-mass index (BMI) lower than 32 kg/m2, with stabilised weight loss for at least 6 months. Women were randomly assigned (1:1) to receive postoperative iron supplementation with two intravenous infusions of 200 mg of iron sucrose (intravenous group) or 100 mg of iron polymaltose complex orally twice a day for 8 weeks (oral group). The primary outcome in both groups was blood haemoglobin concentration at postoperative day 56 after abdominoplasty, with a minimum clinically relevant difference of 1·5 g/dL. Analyses were performed on an intention-to-treat basis. This trial is registered with ClinicalTrials.gov, number NCT01857011, and the Brazilian Clinical Trials Registry, number RBR-2JGRKQ. The trial is completed. FINDINGS: From April 7, 2014, to June 27, 2016, 102 post-bariatric patients were assessed for eligibility. 56 patients were eligible and were randomly assigned, with 28 allocated to each group. Mean baseline haemoglobin concentration was slightly higher in the oral group than in the intravenous group (12·71 g/dL [SD 1·06] vs 12·24 g/L [1·09]), and by post-operative day 56 was 12·54 g/dL (SD 1·18) and 12·80 g/dL (0·81), respectively (mean difference of 0·26 g/dL, 95% CI -0·28 to 0·80; p=0·009 in favour of the intravenous group). The minimum clinically relevant difference in concentrations was not reached. No adverse events were recorded in the intravenous group, whereas in the oral group, constipation was recorded in five (18%) patients, diarrhoea in three (11%), and nausea in one (4%) patient. INTERPRETATION: Postoperative intravenous administration of iron increased haemoglobin concentrations at 56 days post-operatively and reduced iron deficiency, without adverse events. Although superiority of intravenous iron was not shown, intravenous administration might be useful in post-bariatric patients, especially in those who have body-contouring treatment involving a second surgery within a short period of time. Larger trials, and trials using higher intravenous doses of iron, are needed to further assess the potential efficacy and safety of intravenous iron administration after post-bariatric plastic surgery. FUNDING: The São Paulo Research Foundation (FAPESP).
Asunto(s)
Abdominoplastia/efectos adversos , Anemia/tratamiento farmacológico , Anemia/etiología , Cirugía Bariátrica/efectos adversos , Compuestos Férricos/administración & dosificación , Ácido Glucárico/administración & dosificación , Hierro/administración & dosificación , Administración Intravenosa , Administración Oral , Adulto , Anemia/sangre , Anemia/diagnóstico , Biomarcadores , Brasil , Femenino , Compuestos Férricos/efectos adversos , Sacarato de Óxido Férrico , Ácido Glucárico/efectos adversos , Humanos , Hierro/efectos adversos , Persona de Mediana Edad , Factores de Riesgo , Resultado del Tratamiento , Adulto JovenAsunto(s)
Humanos , Masculino , Femenino , Anciano , Compuestos Férricos/efectos adversos , Sales de Hierro/efectos adversos , Óxido Ferrosoférrico/efectos adversos , Ácido Glucárico/efectos adversos , Gluconatos/efectos adversos , Anafilaxia/etiología , Complejo Hierro-Dextran/efectos adversos , Estados Unidos/epidemiología , Compuestos Férricos/administración & dosificación , Riesgo , Óxido Ferrosoférrico/administración & dosificación , Sacarato de Óxido Férrico , Ácido Glucárico/administración & dosificación , Gluconatos/administración & dosificación , Anafilaxia/epidemiología , Inyecciones Intravenosas , Complejo Hierro-Dextran/administración & dosificaciónRESUMEN
BACKGROUND: Anaemia and iron deficiency are common complications following post-bariatric abdominoplasty. Given the low oral absorbability of iron resulting from bariatric surgery, it has been hypothesised that postoperative intravenously administered iron supplementation could be used to treat anaemia and to prevent the development of iron deficiency in these patients. METHODS/DESIGN: In this multicentre open-label randomised clinical trial, 56 adult women undergoing post-bariatric anchor-line abdominoplasty will be allocated at a ratio of 1:1 for postoperative supplementation with two intravenously administered applications of 200 mg of iron saccharate or postoperative supplementation with 100 mg of iron polymaltose complex administered orally, twice a day for 8 weeks. The primary outcome is the difference in mean haemoglobin levels between the two groups at eight postoperative weeks. Secondary outcomes evaluated at one, four and eight postoperative weeks include iron profile, reticulocyte count, overall quality of life measured using the Short-Form 36 Health Survey (SF-36) questionnaire, fatigue measured using the Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-F), adverse effects and postoperative complications. DISCUSSION: This randomised clinical trial aims to evaluate the haematopoietic effectiveness of intravenously administered iron supplementation in patients undergoing post-bariatric abdominoplasty. A more effective recovery of haemoglobin levels could help improve the patients' quality of life and could provide an improved haematological status in preparation for the subsequent and frequent plastic surgeries these patients undergo. TRIAL REGISTRATION: Clinicaltrials.gov Identifier: NCT01857011 (8 May 2013), Universal Trial Number U111-1169-6223, Brazilian Clinical Trials Registry (REBEC): RBR-2JGRKQ .
Asunto(s)
Abdominoplastia/efectos adversos , Anemia/tratamiento farmacológico , Cirugía Bariátrica , Compuestos Férricos/administración & dosificación , Ácido Glucárico/administración & dosificación , Hematínicos/administración & dosificación , Hematopoyesis/efectos de los fármacos , Administración Intravenosa , Administración Oral , Adolescente , Adulto , Anemia/sangre , Anemia/diagnóstico , Biomarcadores/sangre , Brasil , Protocolos Clínicos , Esquema de Medicación , Femenino , Compuestos Férricos/efectos adversos , Sacarato de Óxido Férrico , Ácido Glucárico/efectos adversos , Hematínicos/efectos adversos , Hemoglobinas/metabolismo , Humanos , Persona de Mediana Edad , Calidad de Vida , Proyectos de Investigación , Encuestas y Cuestionarios , Factores de Tiempo , Resultado del Tratamiento , Adulto JovenRESUMEN
Iron is involved in the formation as well as in the scavenging of reactive oxygen and nitrogen species. Thus, iron can induce as well as inhibit both oxidative and nitrosative stress. It also has a key role in reactive oxygen and nitrogen species-mediated apoptosis. We assessed the differences in tyrosine nitration and caspase 3 expression in the liver, heart, and kidneys of rats treated weekly with intravenous ferumoxytol, iron isomaltoside 1000, iron dextran, iron sucrose and ferric carboxymaltose (40 mg iron/kg body weight) for 5 weeks. Nitrotyrosine was quantified in tissue homogenates by Western blotting and the distribution of nitrotyrosine and caspase 3 was assessed in tissue sections by immunohistochemistry. Ferric carboxymaltose and iron sucrose administration did not result in detectable levels of nitrotyrosine or significant levels of caspase 3 vs. control in any of the tissue studied. Nitrotyrosine and caspase 3 levels were significantly (p<0.01) increased in all assessed organs of animals treated with iron dextran and iron isomaltoside 1000, as well as in the liver and kidneys of ferumoxytol-treated animals compared to isotonic saline solution (control). Nitrotyrosine and caspase 3 levels were shown to correlate positively with the amount of Prussian blue-detectable iron(III) deposits in iron dextran- and iron isomaltoside 1000-treated rats but not in ferumoxytol-treated rats, suggesting that iron dextran, iron isomaltoside 1000 and ferumoxytol induce nitrosative (and oxidative) stress as well as apoptosis via different mechanism(s).
Asunto(s)
Apoptosis/efectos de los fármacos , Disacáridos/efectos adversos , Compuestos Férricos/efectos adversos , Óxido Ferrosoférrico/efectos adversos , Ácido Glucárico/efectos adversos , Complejo Hierro-Dextran/efectos adversos , Maltosa/análogos & derivados , Tirosina/análogos & derivados , Administración Intravenosa , Animales , Caspasa 3/biosíntesis , Disacáridos/administración & dosificación , Femenino , Compuestos Férricos/administración & dosificación , Sacarato de Óxido Férrico , Óxido Ferrosoférrico/administración & dosificación , Ácido Glucárico/administración & dosificación , Complejo Hierro-Dextran/administración & dosificación , Riñón/metabolismo , Hígado/metabolismo , Masculino , Maltosa/administración & dosificación , Maltosa/efectos adversos , Modelos Animales , Miocardio/metabolismo , Ratas , Tirosina/metabolismoRESUMEN
When an excess of uronic acid over Cr(VI) is used, the oxidation of D-glucaric acid (Glucar) by Cr(VI) yields D-arabinaric acid, CO2 and Cr(III)-Glucar complex as final redox products. The redox reaction involves the formation of intermediate Cr(IV) and Cr(V) species. The reaction rate increases with [H(+)] and [substrate]. The experimental results indicated that Cr(IV) and Cr(V) are very reactive intermediates since their disappearance rates are much faster than Cr(VI). Cr(IV) and Cr(V) intermediates are involved in fast steps and do not accumulate in the redox reaction of the mixture Cr(VI)-Glucar. Kinetic studies show that the redox reaction between Glucar and Cr(VI) proceeds through a mechanism combining one- and two-electron pathways: Cr(VI) â Cr(IV) â Cr(II) and Cr(VI) â Cr(IV) â Cr(III). After the redox reaction, results show a slow hydrolysis of the Cr(III)-Glucar complex into [Cr(OH2)6](3+). The proposed mechanism is supported by the observation of free radicals, CrO2(2+) (superoxo-Cr(III) ion) and oxo-Cr(V)-Glucar species as reaction intermediates. The continuous-wave electron paramagnetic resonance, CW-EPR, spectra show that five-coordinate oxo-Cr(V) bischelates are formed at pH ≤ 4 with the aldaric acid bound to oxo-Cr(V) through the carboxylate and the α-OH group. A different oxo-Cr(V) species with Glucar was detected at pH 6.0. The high g(iso) value for the last species suggests a mixed coordination species, a five-coordinated oxo-Cr(V) bischelate with one molecule of Glucar acting as a bi-dentate ligand, using the 2-hydroxycarboxylate group, and a second molecule of Glucar with any vic-diolate sites. At pH 7.5 only a very weak EPR signal was observed, which may point to instability of these complexes. This behaviour contrasts with oxo-Cr(V)-uronic species, and must thus be related to the Glucar acyclic structure. In vitro, our studies on the chemistry of oxo-Cr(V)-Glucar complexes can provide information on the nature of the species that are likely to be stabilized in vivo.
Asunto(s)
Cromo/química , Ácido Glucárico/química , Oxidación-Reducción , Cromatos/química , Relación Dosis-Respuesta a Droga , Espectroscopía de Resonancia por Spin del Electrón , Ésteres , Radicales Libres , Concentración de Iones de Hidrógeno , Hidrólisis , Iones , Lactonas/química , Oxígeno/química , Unión Proteica , Especificidad por Sustrato , Temperatura , Rayos UltravioletaRESUMEN
Iron sucrose originator (IS(ORIG)) has been used to treat iron deficiency and iron deficiency anemia for decades. Iron sucrose similars (ISSs) have recently entered the market. In this non-clinical study of non-anemic rats, five doses (40 mg iron/kg body weight) of six ISSs marketed in Asian countries, IS(ORIG) or saline solution (control) were administered intravenously over four weeks to compare their toxicologic effects. Vasodilatory effects, impaired renal function and hepatic damage were only observed in the ISS groups. Significantly elevated serum iron and transferrin saturation levels were observed in the ISS groups suggesting a higher release of iron resulting in higher amounts of non-transferrin bound (free) iron compared to IS(ORIG). This might explain the elevated oxidative stress and increased levels of inflammatory markers and antioxidant enzymes in the liver, heart and kidneys of ISS-treated animals. Physico-chemical analyses showed that the molecular structure of most of the ISSs differed greatly from that of the IS(ORIG). These differences may be responsible for the organ damage and oxidative stress observed in the ISS groups. Significant differences were also found between different lots of a single ISS product. In contrast, polarographic analyses of three different IS(ORIG) lots were identical, indicating that the molecular structure and thus the manufacturing process for IS(ORIG) is highly consistent. Data from this study suggest that ISSs and IS(ORIG) differ significantly. Therefore, before widespread use of these products it would be prudent to evaluate additional non-clinical and/or clinical data proving the safety, therapeutic equivalence and interchangeability of ISSs with IS(ORIG).
Asunto(s)
Modelos Animales de Enfermedad , Compuestos Férricos/administración & dosificación , Compuestos Férricos/toxicidad , Ácido Glucárico/administración & dosificación , Ácido Glucárico/toxicidad , Estrés Oxidativo/fisiología , Anemia Ferropénica/sangre , Anemia Ferropénica/inducido químicamente , Anemia Ferropénica/patología , Animales , Femenino , Compuestos Férricos/sangre , Sacarato de Óxido Férrico , Ácido Glucárico/sangre , Inflamación/sangre , Inflamación/inducido químicamente , Inflamación/patología , Masculino , Estrés Oxidativo/efectos de los fármacos , Ratas , Ratas Sprague-DawleyRESUMEN
The physicochemical characteristics of intravenous iron complexes affect the extent of weakly-bound iron and thus the degree of oxidative stress. The new preparation iron isomaltoside 1000 (IIM) was compared to iron sucrose (IS) and a control group in terms of biochemistry, oxidative stress, inflammatory markers and iron deposition in the liver, heart and kidneys of healthy rats. Renal function was significantly impaired in the IIM group versus both IS and controls. Liver enzymes were also significantly higher in IIM-treated animals versus the other groups, indicative of hepatic injury. Systolic blood pressure was significantly lower following IIM administration compared to IS or control animals. Oxidative stress in the liver, heart and kidneys was greater in the IIM group, as indicated by significantly increased levels of malondialdehyde and antioxidant enzyme activity, accompaniedby a significantly lower ratio of reduced to oxidized glutathione. Microscopy demonstrated more extensive positive staining for iron, and a smaller area of ferritin staining, in the liver, heart and kidneys of rats treated with IIM versus IS.Levels of the inflammatory markers TNF-alpha and IL6 were both significantly higher in the IIM group versus IS in all assessed tissues. These findings indicate that IIM has a less favorable safety profile than IS in healthy rats, adversely affecting iron deposition, oxidative stress and inflammatory responses, with impaired liver and renal function.
Asunto(s)
Disacáridos/toxicidad , Compuestos Férricos/toxicidad , Estrés Oxidativo/efectos de los fármacos , Animales , Biomarcadores/sangre , Presión Sanguínea/efectos de los fármacos , Creatinina/sangre , Disacáridos/administración & dosificación , Disacáridos/farmacocinética , Compuestos Férricos/administración & dosificación , Compuestos Férricos/farmacocinética , Sacarato de Óxido Férrico , Ferritinas/sangre , Ácido Glucárico , Hemoglobinas/metabolismo , Inmunohistoquímica , Inflamación/sangre , Inflamación/inducido químicamente , Inyecciones Intravenosas , Hierro/sangre , Complejo Hierro-Dextran/toxicidad , Riñón/metabolismo , Riñón/patología , Hígado/metabolismo , Hígado/patología , Pruebas de Función Hepática , Masculino , Peso Molecular , Miocardio/metabolismo , Miocardio/patología , Ratas , Ratas Sprague-DawleyRESUMEN
Intravenous (i.v.) iron is associated with a risk of oxidative stress. The effects of ferumoxytol, a recently approved i.v. iron preparation, were compared with those of ferric carboxymaltose, low molecular weight iron dextran and iron sucrose in the liver, kidneys and heart of normal rats. In contrast to iron sucrose and ferric carboxymaltose, low molecular weight iron dextran and ferumoxytol caused renal and hepatic damage as demonstrated by proteinuria and increased liver enzyme levels. Higher levels of oxidative stress in these tissues were also indicated, by significantly higher levels of malondialdehyde, significantly increased antioxidant enzyme activities, and a significant reduction in the reduced to oxidized glutathione ratio. Inflammatory markers were also significantly higher with ferumoxytol and low molecular weight iron dextran rats than iron sucrose and ferric carboxymaltose. Polarographic analysis suggested that ferumoxytol contains a component with a more positive reduction potential, which may facilitate iron-catalyzed formation of reactive oxygen species and thus be responsible for the observed effects. Only low molecular weight iron dextran induced oxidative stress and inflammation in the heart.
Asunto(s)
Compuestos Férricos/toxicidad , Hematínicos/toxicidad , Complejo Hierro-Dextran/toxicidad , Nanopartículas de Magnetita/toxicidad , Maltosa/análogos & derivados , Estrés Oxidativo/efectos de los fármacos , Animales , Antioxidantes/análisis , Presión Sanguínea/efectos de los fármacos , Creatinina/metabolismo , Femenino , Compuestos Férricos/administración & dosificación , Sacarato de Óxido Férrico , Óxido Ferrosoférrico , Ácido Glucárico , Corazón/efectos de los fármacos , Hematínicos/administración & dosificación , Inmunohistoquímica , Inflamación/inducido químicamente , Inyecciones Intravenosas , Complejo Hierro-Dextran/administración & dosificación , Riñón/efectos de los fármacos , Riñón/metabolismo , Peroxidación de Lípido/efectos de los fármacos , Hígado/efectos de los fármacos , Hígado/enzimología , Nanopartículas de Magnetita/administración & dosificación , Masculino , Maltosa/administración & dosificación , Maltosa/toxicidad , Peso Molecular , Proteinuria/inducido químicamente , Ratas , Ratas Sprague-DawleyRESUMEN
Conversion of sucrose into fructose and gluconic acid using invertase, glucose oxidase and catalase was studied by discontinuous (sequential or simultaneous addition of the enzymes) and continuous (simultaneous addition of the enzymes in a 100 kDa-ultrafiltration membrane reactor) processes. The following parameters were varied: concentration of enzymes, initial concentration of substrates (sucrose and glucose), pH, temperature and feeding rate (for continuous process). The highest yield of conversion (100 percent) was attained through the discontinuous (batch) process carried out at pH 4.5 and 37 ºC by the sequential addition of invertase (14.3 U), glucose oxidase (10,000 U) and catalase (59,000 U).
Neste trabalho estudou-se a conversão da sacarose em frutose e ácido glicônico, usando as enzimas invertase, glicose oxidase e catalase, através do emprego de processo descontínuo (com adição sequencial ou simultânea das enzimas) e contínuo (adição simultânea das enzimas em reator com membrana acoplado à membrana de ultrafiltração de 100 kDa). Os parâmetros variados foram: a concentração das enzimas, a concentração inicial dos substratos (sacarose e glicose), o pH, a temperatura e a vazão específica de alimentação (processo contínuo). Obteve-se rendimento de 100 por cento, quando a conversão foi conduzida por processo descontínuo em pH 4,5 e a 37 ºC com adição seqüencial das enzimas invertase (14,3 U), glicose oxidase (10.000 U) e catalase (59.000 U).
Asunto(s)
Ácido Glucárico/química , Catálisis , Fructosa/química , Glucosa Oxidasa/química , Sacarosa/química , Enzimas/química , HidrólisisRESUMEN
Iron supplementation in hemodialysis patients is fundamental to erythropoiesis, but may cause harmful effects. We measured oxidative stress using labile plasma iron (LPI) after parenteral iron replacement in chronic hemodialysis patients. Intravenous iron saccharate (100 mg) was administered in patients undergoing chronic hemodialysis (N = 20). LPI was measured by an oxidant-sensitive fluorescent probe at the beginning of dialysis session (T0), at 10 min (T1), 20 min (T2), and 30 min (T3) after the infusion of iron and at the subsequent session; P < 0.05 was significant. The LPI values were significantly raised according to the time of administration and were transitory: -0.02 +/- 0.20 micromol/L at the beginning of the first session, 0.01 +/- 0.26 micromol/L at T0, 0.03 +/- 0.23 micromol/L at T1, 0.09 +/- 0.28 micromol/L at T2, 0.18 +/- 0.52 micromol/L at T3, and -0.02 +/- 0.16 micromol/L (P = 0.001 to 0.041) at the beginning of the second session. The LPI level in patients without iron supplementation was -0.06 +/- 0.16 micromol/L. Correlations of LPI according to time were T1, T2, and T3 vs. serum iron (P = 0.01, P = 0.007, and P = 0.0025, respectively), and T2 and T3 vs. transferrin saturation (P = 0.001 and P = 0.0003, respectively). LPI generation after intravenous saccharate administration is time-dependent and transitorily detected during hemodialysis. The LPI increment had a positive correlation to iron and transferrin saturation.
Asunto(s)
Compuestos Férricos/farmacología , Hematínicos/farmacología , Hierro/sangre , Diálisis Renal/métodos , Anciano , Anciano de 80 o más Años , Femenino , Compuestos Férricos/administración & dosificación , Sacarato de Óxido Férrico , Ácido Glucárico , Hematínicos/administración & dosificación , Humanos , Infusiones Intravenosas , Fallo Renal Crónico/terapia , Masculino , Persona de Mediana Edad , Factores de TiempoRESUMEN
UNLABELLED: Preliminary findings have suggested that (99m)Tc-glucarate has tumor-seeking properties. The purpose of this study was to explore the potential of this tracer to evaluate malignant head and neck tumors by means of SPECT/CT software fusion imaging. METHODS: Eleven male patients with advanced head and neck carcinoma were included in the study: 9 with locally advanced disease and 2 with clinical suspicion of local relapse. Scanning started 3-6 h after the injection of 1,110 MBq of (99m)Tc-glucarate. Planar and SPECT images of the head, neck, and thorax were acquired. Three-dimensional images were also coregistered with CT. RESULTS: We found (99m)Tc-glucarate uptake in all suspected lesions. SPECT/CT fusion imaging was helpful in all cases for topographically localizing the tracer foci. CONCLUSION: (99m)Tc-glucarate can be considered a potential tracer for the evaluation of patients with head and neck tumors.
Asunto(s)
Ácido Glucárico/análogos & derivados , Neoplasias de Cabeza y Cuello/diagnóstico , Compuestos de Organotecnecio , Anciano , Anciano de 80 o más Años , Neoplasias de Cabeza y Cuello/diagnóstico por imagen , Humanos , Procesamiento de Imagen Asistido por Computador , Masculino , Persona de Mediana Edad , Sensibilidad y Especificidad , Programas Informáticos , Tomografía Computarizada de Emisión de Fotón Único , Tomografía Computarizada por Rayos XRESUMEN
Iron sucrose (Venofer; reference) has a good safety record and is prescribed in patients with anaemia and chronic kidney disease worldwide, but various iron sucrose similar (ISS) preparations are now utilized in clinical practice. This study evaluates possible differences between iron sucrose and ISS preparations on haemodynamic and oxidative stress markers in normal rats. 60 male and 60 female Sprague Dawley rats were divided into four groups and assigned to receive commercially available ISS test 1, ISS test 2, reference or isotonic saline solution (control). A single i.v. dose of iron (40 mg/kg) or saline (equivalent volume) was administered after 24 h and every 7 days for 4 weeks. Blood samples were collected for biological assessment of haemoglobin (Hb), serum iron and percentage transferrin saturation (TSAT), and urine samples were collected to investigate creatinine clearance and proteinuria. Animals were sacrificed after receiving an i.v. dose on days 1, 7 and 28, and kidney, liver, and heart homogenates were then collected to determine antioxidant enzyme levels. Tissues were processed using Prussian blue and immmunohistochemistry techniques to identify iron deposits, tissue ferritin and pro-inflammatory markers. Systolic blood pressure was significantly reduced in the ISS groups relative to the reference and control groups after 24 h and on days 7, 14 and 21 (p < 0.05). Creatinine clearance was reduced (p < 0.01) and proteinuria marked (p < 0.01) in the ISS groups at 24 h and on days 7 and 28 relative to the reference and control groups which did not differ throughout the study. Liver enzymes were also increased in the ISS groups at 24 h and on days 7 and 28. Both ISS test 1 and ISS test 2 groups presented a significant increase in catalase, thiobarbituric reactive species, Cu, Zn-superoxide dismutase (CuZnSOD) and glutathione peroxidase activity, and a decrease in glutathione levels (p < 0.01) in the liver, heart and kidney at 24 h and on day 7 relative to the reference and control groups. Serum iron and percentage TSAT were elevated in all groups (except control) (p < 0.01) but no differences in Hb concentration were observed between them. Finally, levels of the proinflammatory markers TNF-alpha and IL6 were significantly elevated in the ISS groups (liver, heart and kidney) compared with the reference and control groups on day 28 (p < 0.01). These findings suggest significant differences between the reference and ISS test 1/ISS test 2 regarding oxidative stress and the inflammatory responses of liver, heart and kidneys in normal rats. A possible explanation for these observations could be the stability of the iron complex.
Asunto(s)
Compuestos Férricos/farmacología , Hematínicos/farmacología , Animales , Biomarcadores , Presión Sanguínea/efectos de los fármacos , Química Farmacéutica , Creatinina/orina , Femenino , Compuestos Férricos/administración & dosificación , Sacarato de Óxido Férrico , Ferritinas/metabolismo , Ácido Glucárico , Corazón/efectos de los fármacos , Hematínicos/administración & dosificación , Hemodinámica/efectos de los fármacos , Inmunohistoquímica , Inflamación/metabolismo , Inyecciones Intravenosas , Riñón/efectos de los fármacos , Riñón/metabolismo , Hígado/efectos de los fármacos , Hígado/enzimología , Hígado/metabolismo , Masculino , Miocardio/metabolismo , Estrés Oxidativo/efectos de los fármacos , Proteinuria/metabolismo , Ratas , Ratas Sprague-DawleyRESUMEN
Connectivity of the glycocalyx covering of small communities of Acidithiobacillus ferrooxidans bacteria deposited on hydrophilic mica plates was imaged by atomic force microscopy. When part of the coverage was removed by water rinsing, an insoluble structure formed by corrals surrounding each individual bacterium was observed. A collective ring structure with clustered bacteria (>or=3) was observed, which indicates that the bacteria perceived the neighborhood in order to grow a protective structure that results in smaller production of exopolysaccharides material. The most surprising aspect of these collective corral structures was that they occur at a low bacterial cell density. The deposited layers were also analyzed by confocal Raman microscopy and shown to contain polysaccharides, protein, and glucoronic acid.
Asunto(s)
Acidithiobacillus/fisiología , Glicocálix/química , Glicocálix/microbiología , Microscopía de Fuerza Atómica/métodos , Percepción de Quorum/fisiología , Proteínas Bacterianas/análisis , Ácido Glucárico/análisis , Microscopía Confocal , Polisacáridos Bacterianos/análisisRESUMEN
OBJECTIVES: Our objective was to evaluate in a double-blind, randomized, placebo-controlled study possible modifications in NT-pro-brain natriuretic peptide (NT-proBNP) and C-reactive protein (CRP) levels together with clinical and functional parameters, in a group of anemic patients with chronic heart failure (CHF) and chronic renal failure (CRF) receiving intravenous iron therapy, without recombinant human erythropoietin (rhEPO), versus placebo. BACKGROUND: Chronic heart failure and CRF associated with absolute or relative iron deficiency anemia is a common problem. This situation is linked with a variable inflammatory status. Both NT-proBNP and CRP are recognized markers for left ventricular dysfunction and inflammatory status, respectively. In this double-blind, randomized, placebo-controlled study, modifications in NT-proBNP and CRP level and clinical and functional parameters, in anemic patients with CHF and CRF receiving intravenous iron therapy, without rhEPO, versus placebo were evaluated. METHODS: Forty patients with hemoglobin (Hb) <12.5 g/dl, transferrin saturation <20%, ferritin <100 ng/ml, creatinine clearance (CrCl) <90 ml/min, and left ventricular ejection fraction (LVEF) < or =35% were randomized into 2 groups (n = 20 for each). For 5 weeks, group A received isotonic saline solution and group B received iron sucrose complex, 200 mg weekly. Minnesota Living with Heart Failure Questionnaire (MLHFQ) and 6-min walk (6MW) test were performed. NT-pro brain natriuretic peptide and CRP were evaluated throughout the study. No patients received erythroprotein any time. RESULTS: After 6 months follow-up, group B showed better hematology values and CrCl (p < 0.01) and lower NT-proBNP (117.5 +/- 87.4 pg/ml vs. 450.9 +/- 248.8 pg/ml, p < 0.01) and CRP (2.3 +/- 0.8 mg/l vs. 6.5 +/- 3.7 mg/l, p < 0.01). There was a correlation initially (p < 0.01) between Hb and NT-proBNP (group A: r = -0.94 and group B: r = -0.81) and after 6 months only in group A: r = -0.80. Similar correlations were observed with Hb and CRP. Left ventricular ejection fraction percentage (35.7 +/- 4.7 vs. 28.8 +/- 2.4), MLHFQ score, and 6MW test were all improved in group B (p < 0.01). Additionally, group B had fewer hospitalizations: 0 of 20 versus group A, 5 of 20 (p < 0.01; relative risk = 2.33). CONCLUSIONS: Intravenous iron therapy without rhEPO substantially reduced NT-proBNP and inflammatory status in anemic patients with CHF and moderate CRF. This situation was associated with an improvement in LVEF, NYHA functional class, exercise capacity, renal function, and better quality of life.
Asunto(s)
Anemia Ferropénica/tratamiento farmacológico , Anemia Ferropénica/etiología , Compuestos Férricos/administración & dosificación , Insuficiencia Cardíaca/complicaciones , Hematínicos/administración & dosificación , Péptido Natriurético Encefálico/efectos de los fármacos , Fragmentos de Péptidos/efectos de los fármacos , Insuficiencia Renal Crónica/complicaciones , Anciano , Anciano de 80 o más Años , Anemia Ferropénica/sangre , Biomarcadores/metabolismo , Proteína C-Reactiva/efectos de los fármacos , Proteína C-Reactiva/metabolismo , Método Doble Ciego , Tolerancia al Ejercicio , Femenino , Sacarato de Óxido Férrico , Estudios de Seguimiento , Ácido Glucárico , Insuficiencia Cardíaca/metabolismo , Insuficiencia Cardíaca/fisiopatología , Hospitalización , Humanos , Infusiones Intravenosas , Masculino , Persona de Mediana Edad , Péptido Natriurético Encefálico/metabolismo , Fragmentos de Péptidos/metabolismo , Proyectos Piloto , Estudios Prospectivos , Calidad de Vida , Insuficiencia Renal Crónica/metabolismo , Insuficiencia Renal Crónica/fisiopatología , Resultado del TratamientoRESUMEN
BACKGROUND: Anemia is a common finding in heart failure (HF) patients and has been associated with increased morbidity and mortality. It is generally denominated as anemia of chronic disease (ACD), but the association with true ferropenic anemia is common. Many studies have investigated the effects of treating anemia in HF patients with either erythropoietin alone or combination of erythropoietin and intravenous iron. However, the effect of iron supplementation alone in HF patients with ACD, ferropenic anemia, or both is unknown. METHODS AND RESULTS: IRON-HF study is a multicenter, investigator initiated, randomized, double-blind, placebo controlled trial that will enroll anemic HF patients with relatively preserved renal function, low transferrin saturation, low iron levels, and low to moderately elevated ferritin levels. Interventions are iron sucrose intravenously 200 mg once per week for 5 weeks, ferrous sulfate 200 mg by mouth 3 times per day for 8 weeks, or placebo. The primary objective is to assess the impact of iron supplementation (intravenously or by mouth) compared with placebo in HF patients with anemia from deficient iron availability. The primary end point is variation of peak oxygen consumption assessed by ergospirometry over 3-month follow-up. Secondary end points include functional class, brain natriuretic peptide levels, quality of life scores, left ventricular ejection fraction, adverse events, HF hospitalization, and death. CONCLUSIONS: The results of IRON-HF should help to clarify the potential clinical impact of mild to moderate anemia correction in HF patients.
Asunto(s)
Anemia Ferropénica/tratamiento farmacológico , Compuestos Férricos/uso terapéutico , Insuficiencia Cardíaca/complicaciones , Hematínicos/uso terapéutico , Adulto , Anemia Ferropénica/etiología , Método Doble Ciego , Sacarato de Óxido Férrico , Ácido Glucárico , Humanos , Estudios Prospectivos , Proyectos de InvestigaciónRESUMEN
El cáncer broncopulmonar (CBP) es la primera causa de muerte por cáncer en el mundo. El CBP a células no pequeñas (CBPCNP) representa el 80 por ciento de la patología neoplásica pulmonar, presentándose frecuentemente al diagnóstico como localmente avanzando o metastásico. Dos tercios se presentan en etapa avanzada, inoperable, integrando la quimioterapia (QT) el tratamiento. Responden favorablemente 30 por ciento de dichos pacientes; los restantes recibirán agentes antineoplásicos sin beneficio terapéutico pero con sus efectos adversos. Ante dicha situación sería de gran relevancia clínica poder contar con una técnica funcional que permitiera evaluar la respuesta a la terapia oncoespecífica. Por tal motivo, nuestro grupo ha desarrollado un protocolo clínico para investigar la capacidad del 99mTc-Glucarato en la evaluación precoz de la respuesta a la QT en este grupo de pacientes. Para ello, es necesario demostrar previamente que las lesiones primarias y secundarias del CBPCNP pueden acumular este trazador. La presente nota clínica describe por vez primera en la literatura indexada la capacidad del 99mTc-Glucarato como marcador funcional de lesiones primarias y metastásicas del CBPCNP.
Asunto(s)
Humanos , Masculino , Adulto , Tomografía Computarizada de Emisión de Fotón Único , Compuestos de Organotecnecio , Neoplasias Pulmonares , Relación Dosis-Respuesta a Droga , Ácido Glucárico , Huesos , Biomarcadores de Tumor , Metástasis de la Neoplasia , Neoplasias Pulmonares/tratamiento farmacológico , Neoplasias Óseas/secundario , RadiofármacosRESUMEN
BACKGROUND: Iron sucrose (Fe-S) and low-molecular-weight iron dextran (Fe-D) have been used successfully in the treatment of anaemia in chronic kidney disease patients. However, some side effects, such as endothelial cell dysfunction have been reported. Mechanisms by which iron can induce endothelial cell damage have not been completely understood. This study was designed to examine the effect of Fe-S and Fe-D on bovine aortic endothelial cells in vitro. METHODS: Cell proliferation was determined by [3H] thymidine incorporation, cytotoxicity by lactate dehydrogenase, pro-Caspase-3 by immunoblotting; and Caspase-3 activity using a colorimetric assay. Expression of the apoptosis stress pathway proteins Bcl-2 and Bax and cycle arrest proteins p53 and p21WAF/CIP1 were examined by immunoblot. Cell apoptosis was tested by terminal deoxynucleotidyltransferase-mediated nick-end labelling (TUNEL) and DNA fragmentation. RESULTS: Both iron preparations inhibited cell proliferation. This effect was more important and occurred at lower concentrations in Fe-S than Fe-D cultured cells. Expression of p53 and p21WAF/CIP1 increased in cells incubated with Fe-S, but not with Fe-D. Bcl-2 expression was significantly down-regulated in cells incubated with Fe-S in comparison with Fe-D, while Bax expression was not modified by the iron compounds. Pro-Caspase-3 expression and Caspase-3 activity increased only in cells treated with Fe-S. Apoptosis was present in cells treated with Fe-S. CONCLUSIONS: Our results demonstrate that Fe-S exerts a greater inhibitory effect on endothelial cell proliferation than Fe-D. The mechanisms involved in this process may be related, at least in part, to over expression of proteins related to the cell cycle arrest and apoptosis stress pathway.
Asunto(s)
Apoptosis/fisiología , Células Endoteliales/metabolismo , Endotelio Vascular/metabolismo , Hierro/fisiología , Estrés Fisiológico/metabolismo , Animales , Bovinos , Proliferación Celular , Células Cultivadas , Endotelio Vascular/citología , Compuestos Férricos/farmacología , Sacarato de Óxido Férrico , Ácido Glucárico , Complejo Hierro-Dextran/farmacología , Transducción de Señal/fisiologíaRESUMEN
Since the effect of iron (Fe) on the cariogenicity of sucrose in humans is unexplored, this study assessed in situ the effect of Fe co-crystallized with sucrose (Fe-sucrose) topically applied in vitro on the acidogenicity, biochemical and microbiological composition of the dental biofilm formed in vivo and on the demineralization of the enamel. During two phases of 14 days each, 16 volunteers wore palatal appliances containing blocks of human enamel, which were submitted to four groups of separate treatments: (1) water; (2) 20% sucrose; (3) 20% (w/v) sucrose plus 18 microg Fe/ml, and (4) 20% (w/v) sucrose plus 70 microg Fe/ml. The solutions were dripped onto the blocks 8 times per day. The biofilms formed on the blocks were analyzed with respect to acidogenicity, biochemical and microbiological composition. Mineral loss was determined on enamel by surface and cross-sectional microhardness. Lower demineralization was found in the blocks subjected to Fe-sucrose (70 microg Fe/ml) than in those treated with sucrose (p < 0.05). This concentration of Fe also reduced significantly the populations of mutans streptococci in the biofilm formed on the blocks. In conclusion, our data suggest that Fe may reduce in situ the cariogenic potential of sucrose and the effect seems to be related to the reduction in the populations of mutans streptococci in the dental biofilm formed.